vs
ADMA BIOLOGICS, INC.（ADMA）与Adaptive Biotechnologies Corp（ADPT）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是Adaptive Biotechnologies Corp的1.9倍（$139.2M vs $71.7M）。ADMA BIOLOGICS, INC.净利率更高（35.5% vs -18.9%，领先54.4%）。Adaptive Biotechnologies Corp同比增速更快（51.0% vs 18.4%）。ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $1.4M）。过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs 30.4%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
ADMA vs ADPT — 直观对比
营收规模更大
ADMA
是对方的1.9倍
$71.7M
营收增速更快
ADPT
高出32.7%
18.4%
净利率更高
ADMA
高出54.4%
-18.9%
自由现金流更多
ADMA
多$33.1M
$1.4M
两年增速更快
ADPT
近两年复合增速
30.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $71.7M |
| 净利润 | $49.4M | $-13.6M |
| 毛利率 | 63.8% | 74.6% |
| 营业利润率 | 45.1% | -17.8% |
| 净利率 | 35.5% | -18.9% |
| 营收同比 | 18.4% | 51.0% |
| 净利润同比 | -55.9% | 59.7% |
| 每股收益（稀释后） | $0.20 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAADPT
| Q4 25 | $139.2M | $71.7M | ||
| Q3 25 | $134.2M | $94.0M | ||
| Q2 25 | $122.0M | $58.9M | ||
| Q1 25 | $114.8M | $52.4M | ||
| Q4 24 | $117.5M | $47.5M | ||
| Q3 24 | $119.8M | $46.4M | ||
| Q2 24 | $107.2M | $43.2M | ||
| Q1 24 | $81.9M | $41.9M |
净利润ADMAADPT
| Q4 25 | $49.4M | $-13.6M | ||
| Q3 25 | $36.4M | $9.5M | ||
| Q2 25 | $34.2M | $-25.6M | ||
| Q1 25 | $26.9M | $-29.9M | ||
| Q4 24 | $111.9M | $-33.7M | ||
| Q3 24 | $35.9M | $-32.1M | ||
| Q2 24 | $32.1M | $-46.2M | ||
| Q1 24 | $17.8M | $-47.5M |
毛利率ADMAADPT
| Q4 25 | 63.8% | 74.6% | ||
| Q3 25 | 56.3% | 80.7% | ||
| Q2 25 | 55.1% | 69.4% | ||
| Q1 25 | 53.2% | 67.6% | ||
| Q4 24 | 53.9% | 62.0% | ||
| Q3 24 | 49.8% | 64.1% | ||
| Q2 24 | 53.6% | 55.3% | ||
| Q1 24 | 47.8% | 56.9% |
营业利润率ADMAADPT
| Q4 25 | 45.1% | -17.8% | ||
| Q3 25 | 38.0% | 10.9% | ||
| Q2 25 | 35.1% | -42.5% | ||
| Q1 25 | 30.4% | -56.4% | ||
| Q4 24 | 32.6% | -71.3% | ||
| Q3 24 | 33.1% | -70.3% | ||
| Q2 24 | 36.6% | -109.6% | ||
| Q1 24 | 26.7% | -116.5% |
净利率ADMAADPT
| Q4 25 | 35.5% | -18.9% | ||
| Q3 25 | 27.1% | 10.2% | ||
| Q2 25 | 28.1% | -43.5% | ||
| Q1 25 | 23.4% | -56.9% | ||
| Q4 24 | 95.2% | -71.0% | ||
| Q3 24 | 30.0% | -69.1% | ||
| Q2 24 | 29.9% | -107.0% | ||
| Q1 24 | 21.7% | -113.5% |
每股收益（稀释后）ADMAADPT
| Q4 25 | $0.20 | $-0.08 | ||
| Q3 25 | $0.15 | $0.06 | ||
| Q2 25 | $0.14 | $-0.17 | ||
| Q1 25 | $0.11 | $-0.20 | ||
| Q4 24 | $0.45 | $-0.22 | ||
| Q3 24 | $0.15 | $-0.22 | ||
| Q2 24 | $0.13 | $-0.31 | ||
| Q1 24 | $0.08 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $70.5M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $218.8M |
| 总资产 | $624.2M | $512.7M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAADPT
| Q4 25 | $87.6M | $70.5M | ||
| Q3 25 | $61.4M | $55.0M | ||
| Q2 25 | $90.3M | $43.2M | ||
| Q1 25 | $71.6M | $50.6M | ||
| Q4 24 | $103.1M | $47.9M | ||
| Q3 24 | $86.7M | $38.1M | ||
| Q2 24 | $88.2M | $59.8M | ||
| Q1 24 | $45.3M | $71.2M |
总债务ADMAADPT
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMAADPT
| Q4 25 | $477.3M | $218.8M | ||
| Q3 25 | $431.2M | $204.4M | ||
| Q2 25 | $398.3M | $179.7M | ||
| Q1 25 | $373.4M | $190.4M | ||
| Q4 24 | $349.0M | $202.7M | ||
| Q3 24 | $231.9M | $223.8M | ||
| Q2 24 | $188.3M | $241.6M | ||
| Q1 24 | $153.7M | $274.9M |
总资产ADMAADPT
| Q4 25 | $624.2M | $512.7M | ||
| Q3 25 | $568.7M | $490.6M | ||
| Q2 25 | $558.4M | $496.6M | ||
| Q1 25 | $510.6M | $510.9M | ||
| Q4 24 | $488.7M | $539.4M | ||
| Q3 24 | $390.6M | $558.5M | ||
| Q2 24 | $376.4M | $584.9M | ||
| Q1 24 | $350.9M | $620.3M |
负债/权益比ADMAADPT
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $2.1M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $1.4M |
| 自由现金流率自由现金流/营收 | 24.8% | 2.0% |
| 资本支出强度资本支出/营收 | 0.8% | 0.9% |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | $-48.9M |
8季度趋势，按日历期对齐
经营现金流ADMAADPT
| Q4 25 | $35.6M | $2.1M | ||
| Q3 25 | $13.3M | $-7.1M | ||
| Q2 25 | $21.1M | $-12.4M | ||
| Q1 25 | $-19.7M | $-28.5M | ||
| Q4 24 | $50.2M | $-12.5M | ||
| Q3 24 | $25.0M | $-27.1M | ||
| Q2 24 | $45.6M | $-17.3M | ||
| Q1 24 | $-2.2M | $-38.4M |
自由现金流ADMAADPT
| Q4 25 | $34.6M | $1.4M | ||
| Q3 25 | $-1.1M | $-7.5M | ||
| Q2 25 | $18.7M | $-13.1M | ||
| Q1 25 | $-24.4M | $-29.7M | ||
| Q4 24 | $47.5M | $-12.6M | ||
| Q3 24 | $24.0M | $-27.4M | ||
| Q2 24 | $43.6M | $-19.0M | ||
| Q1 24 | $-4.6M | $-39.9M |
自由现金流率ADMAADPT
| Q4 25 | 24.8% | 2.0% | ||
| Q3 25 | -0.8% | -8.0% | ||
| Q2 25 | 15.3% | -22.2% | ||
| Q1 25 | -21.2% | -56.7% | ||
| Q4 24 | 40.4% | -26.5% | ||
| Q3 24 | 20.0% | -59.0% | ||
| Q2 24 | 40.7% | -44.1% | ||
| Q1 24 | -5.6% | -95.2% |
资本支出强度ADMAADPT
| Q4 25 | 0.8% | 0.9% | ||
| Q3 25 | 10.7% | 0.4% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 2.4% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.9% | 0.7% | ||
| Q2 24 | 1.9% | 4.0% | ||
| Q1 24 | 2.9% | 3.6% |
现金转化率ADMAADPT
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | -0.75× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
暂无分部数据
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
